These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21369867)

  • 1. EGFR trans-activation by urotensin II receptor is mediated by β-arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy.
    Esposito G; Perrino C; Cannavo A; Schiattarella GG; Borgia F; Sannino A; Pironti G; Gargiulo G; Di Serafino L; Franzone A; Scudiero L; Grieco P; Indolfi C; Chiariello M
    Basic Res Cardiol; 2011 Jun; 106(4):577-89. PubMed ID: 21369867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urotensin II prevents cardiomyocyte apoptosis induced by doxorubicin via Akt and ERK.
    Chen YL; Loh SH; Chen JJ; Tsai CS
    Eur J Pharmacol; 2012 Apr; 680(1-3):88-94. PubMed ID: 22329895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection.
    Noma T; Lemaire A; Naga Prasad SV; Barki-Harrington L; Tilley DG; Chen J; Le Corvoisier P; Violin JD; Wei H; Lefkowitz RJ; Rockman HA
    J Clin Invest; 2007 Sep; 117(9):2445-58. PubMed ID: 17786238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follicle-stimulating hormone (FSH) activates extracellular signal-regulated kinase phosphorylation independently of beta-arrestin- and dynamin-mediated FSH receptor internalization.
    Piketty V; Kara E; Guillou F; Reiter E; Crepieux P
    Reprod Biol Endocrinol; 2006 Jun; 4():33. PubMed ID: 16787538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases.
    Onan D; Pipolo L; Yang E; Hannan RD; Thomas WG
    Mol Endocrinol; 2004 Sep; 18(9):2344-54. PubMed ID: 15205471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of beta-arrestin 1 in the metastatic progression of colorectal cancer.
    Buchanan FG; Gorden DL; Matta P; Shi Q; Matrisian LM; DuBois RN
    Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1492-7. PubMed ID: 16432186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy.
    Zhai P; Galeotti J; Liu J; Holle E; Yu X; Wagner T; Sadoshima J
    Circ Res; 2006 Sep; 99(5):528-36. PubMed ID: 16902180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel EGFR inhibitors attenuate cardiac hypertrophy induced by angiotensin II.
    Peng K; Tian X; Qian Y; Skibba M; Zou C; Liu Z; Wang J; Xu Z; Li X; Liang G
    J Cell Mol Med; 2016 Mar; 20(3):482-94. PubMed ID: 26762600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obestatin stimulates Akt signalling in gastric cancer cells through beta-arrestin-mediated epidermal growth factor receptor transactivation.
    Alvarez CJ; Lodeiro M; Theodoropoulou M; Camiña JP; Casanueva FF; Pazos Y
    Endocr Relat Cancer; 2009 Jun; 16(2):599-611. PubMed ID: 19153210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-arrestin 2 is required for B1 receptor-dependent post-translational activation of inducible nitric oxide synthase.
    Kuhr FK; Zhang Y; Brovkovych V; Skidgel RA
    FASEB J; 2010 Jul; 24(7):2475-83. PubMed ID: 20228252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Midkine Deteriorates Cardiac Remodeling via Epidermal Growth Factor Receptor Signaling in Chronic Kidney Disease.
    Honda Y; Shishido T; Takahashi T; Watanabe T; Netsu S; Kinoshita D; Narumi T; Kadowaki S; Nishiyama S; Takahashi H; Arimoto T; Miyamoto T; Kishida S; Kadomatsu K; Takeishi Y; Kubota I
    Hypertension; 2016 May; 67(5):857-65. PubMed ID: 26975703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biased signaling regulates the pleiotropic effects of the urotensin II receptor to modulate its cellular behaviors.
    Brulé C; Perzo N; Joubert JE; Sainsily X; Leduc R; Castel H; Prézeau L
    FASEB J; 2014 Dec; 28(12):5148-62. PubMed ID: 25183668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation.
    Liao Y; Zhao H; Ogai A; Kato H; Asakura M; Kim J; Asanuma H; Minamino T; Takashima S; Kitakaze M
    Hypertens Res; 2008 Feb; 31(2):335-44. PubMed ID: 18360054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. beta-Arrestin mediates beta1-adrenergic receptor-epidermal growth factor receptor interaction and downstream signaling.
    Tilley DG; Kim IM; Patel PA; Violin JD; Rockman HA
    J Biol Chem; 2009 Jul; 284(30):20375-86. PubMed ID: 19509284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAR-1 activation rescues astrocytes through the PI3K/Akt signaling pathway from chemically induced apoptosis that is exacerbated by gene silencing of β-arrestin 1.
    Zhu Z; Reiser G
    Neurochem Int; 2014 Feb; 67():46-56. PubMed ID: 24378649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KISS1R signals independently of Gαq/11 and triggers LH secretion via the β-arrestin pathway in the male mouse.
    Ahow M; Min L; Pampillo M; Nash C; Wen J; Soltis K; Carroll RS; Glidewell-Kenney CA; Mellon PL; Bhattacharya M; Tobet SA; Kaiser UB; Babwah AV
    Endocrinology; 2014 Nov; 155(11):4433-46. PubMed ID: 25147978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of the exact molecular requirements for type 1 angiotensin receptor epidermal growth factor receptor transactivation and cardiomyocyte hypertrophy.
    Smith NJ; Chan HW; Qian H; Bourne AM; Hannan KM; Warner FJ; Ritchie RH; Pearson RB; Hannan RD; Thomas WG
    Hypertension; 2011 May; 57(5):973-80. PubMed ID: 21383310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Helix I of beta-arrestin is involved in postendocytic trafficking but is not required for membrane translocation, receptor binding, and internalization.
    Dinh DT; Qian H; Seeber R; Lim E; Pfleger K; Eidne KA; Thomas WG
    Mol Pharmacol; 2005 Feb; 67(2):375-82. PubMed ID: 15523053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodynamic effects of chronic urotensin II administration in animals with and without aorto-caval fistula.
    Harris GS; Lust RM; Katwa LC
    Peptides; 2007 Aug; 28(8):1483-9. PubMed ID: 17553596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitor of G protein-coupled receptor kinase 2 normalizes vascular endothelial function in type 2 diabetic mice by improving β-arrestin 2 translocation and ameliorating Akt/eNOS signal dysfunction.
    Taguchi K; Matsumoto T; Kamata K; Kobayashi T
    Endocrinology; 2012 Jul; 153(7):2985-96. PubMed ID: 22581458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.